Going Global with Gilead Sciences Inc.
Simon Bonouvrie
Cadence Capital
Gilead Sciences (NASDAQ: GILD) was the first offshore position in the Cadence portfolio, initiated in mid-2014. We initiated the position at a price of approx US$82 and have added to the stock since then. The stock is currently US$122. Gilead is a large US biotech stock specialising in antiviral drugs to treat patients suffering from HIV, hepatitis C, influenza and other medical conditions. Gilead's market capitalisation is US$180b, making it larger than any company listed on the ASX. Read more here (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Simon joined Cadence Capital in 2013 as a Portfolio Manager. Prior to joining Cadence, Simon was a Portfolio Manager at Platypus Asset Management for 8 years. After completing a Bachelor of Engineering (Chemical) (Honours), Bachelor of Commerce and a Masters of Commerce (Finance), Simon worked as an Institutional Banking Associate at Commonwealth Bank of Australia and an Industry Analyst at ANZ Banking Group, prior to entering funds management.
Simon Bonouvrie
Cadence Capital
Simon joined Cadence Capital in 2013 as a Portfolio Manager. Prior to joining Cadence, Simon was a Portfolio Manager at Platypus Asset Management for 8 years. After completing a Bachelor of Engineering (Chemical) (Honours), Bachelor of Commerce...
Expertise
No areas of expertise
Simon Bonouvrie
Cadence Capital
Simon joined Cadence Capital in 2013 as a Portfolio Manager. Prior to joining Cadence, Simon was a Portfolio Manager at Platypus Asset Management for 8 years. After completing a Bachelor of Engineering (Chemical) (Honours), Bachelor of Commerce...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment